Longeveron Inc. SEC filings LGVN
Longeveron Inc. has 532 filings in SEC EDGAR's recent list, going back to Nov 6, 2017. Its latest annual report, Form ARS, was filed on May 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 17, 2026 | — |
| CORRESP | Letter to the SEC | Apr 15, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2026 | — |
| D | Filing | Mar 25, 2026 | — |
| EFFECT | Filing | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 25, 2025 | — |
| DRS | Filing | Jul 21, 2025 | — |
| EFFECT | Filing | Apr 4, 2025 | — |
| CORRESP | Letter to the SEC | Apr 2, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2025 | — |
| EFFECT | Filing | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 9, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2024 | — |
| D | Filing | Jul 23, 2024 | — |
| EFFECT | Filing | Jul 9, 2024 | — |
| CORRESP | Letter to the SEC | Jul 5, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2024 | — |
| D | Filing | Jun 25, 2024 | — |
| EFFECT | Filing | May 21, 2024 | — |
| CORRESP | Letter to the SEC | May 17, 2024 | — |
| UPLOAD | Letter from the SEC | May 6, 2024 | — |
| D | Filing | Apr 25, 2024 | — |
| EFFECT | Filing | Apr 17, 2024 | — |
| CORRESP | Letter to the SEC | Apr 16, 2024 | — |
| EFFECT | Filing | Apr 8, 2024 | — |
| CORRESP | Letter to the SEC | Apr 8, 2024 | — |
| CORRESP | Letter to the SEC | Apr 8, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 27, 2024 | — |
| CORRESP | Letter to the SEC | Mar 1, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2024 | — |
| D | Filing | Jan 8, 2024 | — |
| EFFECT | Filing | Nov 21, 2023 | — |
| CORRESP | Letter to the SEC | Nov 17, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2023 | — |
| D | Filing | Oct 24, 2023 | — |
| 25-NSE | Delisting notice | Sep 21, 2023 | — |
| CERT | Filing | Aug 16, 2023 | — |
| EFFECT | Filing | Aug 14, 2023 | — |
| 8-A12B | For registration of certain classes | Aug 14, 2023 | — |
| CORRESP | Letter to the SEC | Aug 11, 2023 | — |
| CORRESP | Letter to the SEC | Jul 28, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2023 | — |
| EFFECT | Filing | Apr 14, 2022 | — |
| CORRESP | Letter to the SEC | Apr 12, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 12, 2022 | — |
| EFFECT | Filing | Dec 22, 2021 | — |
| CORRESP | Letter to the SEC | Dec 20, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 17, 2021 | — |
| D | Filing | Dec 13, 2021 | — |
| EFFECT | Filing | Feb 11, 2021 | — |
| CERT | 8a cert | Feb 11, 2021 | — |
| 8-A12B | Registration of certain classes of securities | Feb 11, 2021 | — |
| CORRESP | Letter to the SEC | Feb 10, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2021 | — |
| CORRESP | Letter to the SEC | Feb 9, 2021 | — |
| CORRESP | Letter to the SEC | Feb 9, 2021 | — |
| CORRESP | Letter to the SEC | Feb 3, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Jan 19, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 14, 2021 | — |
| DRSLTR | Filing | Dec 30, 2020 | — |
| DRS/A | Filing | Dec 30, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 10, 2020 | — |
| DRS | Filing | Nov 12, 2020 | — |
| D | Filing | Feb 6, 2020 | — |
| D/A | Filing | Feb 6, 2020 | — |
| D/A | Filing | Apr 5, 2018 | — |
| D | Filing | Nov 6, 2017 | — |
Showing 70 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LGVN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1721484
- Former names
- LONGEVERON LLC (until Feb 10, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.